Medtronic separates Diabetes unit via MiniMed IPO; tariff refunds pending, tax cushion narrows

Filed June 18, 2026 · Period ending April 24, 2026 · Compared to 10-K Jun 20, 2025 · ~2 min read

Key Changes

• high

  Diabetes Business separated via MiniMed IPO in March 2026, ahead of the 18-month timeline announced in May 2025. Medtronic retains ~90% ownership, creating $609M in noncontrolling interests and ongoing separation costs, dis-synergies, and transition-agreement risks.

  Business: Diabetes separation completion verify on EDGAR →
• high

  Medical Surgical reporting unit's goodwill fair-value cushion narrowed to 12% (from 20% baseline range), with $20.0B of goodwill at risk. MiniMed's post-IPO stock decline raises future impairment risk if fair value deteriorates further.

  MD&A: Goodwill impairment sensitivity verify on EDGAR →
• high

  Puerto Rico tax litigation remanded to Tax Court in September 2025; parties requested stay to discuss potential settlement. New IRS audit for FY2017-2019 leaves Puerto Rico income allocation, intercompany debt rates, and foreign tax credits unresolved. Uncertain tax position reserve increased $49M to $2.951B.

  Controls: Puerto Rico tax litigation & IRS audit verify on EDGAR →